Results of Sublingual Vs. Vaginal Misoprostol in the Management of Early Miscarriage

Abstract

Objective: To ascertain the results of sublingual and vaginal misoprostol in the treatment of early miscarriage. Background: Roughly 12% of pregnancies end in clinical miscarriage. In particular, medical evacuation of a missed abortion is appropriate for women who do not want to be taken to the hospital or have surgery performed under general anesthesia. It is a safe, effective, and economical alternative to surgical uterine evacuation. Study Design: randomized control trail. Place And Duration: This study was conducted in Liaquat University of Medical and Health Sciences Jamshoro from December 2022 to December 2023. Methodology: This study was conducted on 70 – 70 patients in each group that is vaginal misoprostol and sublingual misoprostol groups. Patients fulfilling the criteria for early miscarriage were included however, all the patients with history of ectopic pregnancy, patients having intrauterine contraceptive device, or having renal, cardiac or hepatic disease were excluded. The data was entered and analyzed using Microsoft excel. Results: In the vaginal misoprostol group, the mean age of the patients was 22.3±4.1 years, whereas in the sublingual misoprostol group, it was 23.7±3.8 years. There were 47(67.14%) successful cases in vaginal misoprostol group while 52 (74.29%) in sublingual misoprostol group. However, 23(32.86%) and 18(25.71%) cases were unsuccessful in vaginal misoprostol group and sublingual misoprostol group respectively Conclusion: Compared to the vaginal route the sublingual is numerical more successfully however there in absence statistical significance it was concluded that both the routes are nearly similar in terms of efficacy.